Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.60 |
| ▸ | HTR1D | P28221 | 2/20 | 0.60 |
| ▸ | HTR1B | P28222 | 2/20 | 0.60 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 1/20 | 0.60 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513682 | 0.83 | HTR2A (0.67) | MEN1KMT2AMAPTCYP3A4AHR | |
| SCHEMBL5020054 | 0.83 | MEN1 (0.69) | MEN1KMT2AMAPTCYP3A4AHR | |
| SCHEMBL29413080 | 0.83 | MEN1 (0.69) | MEN1KMT2AMAPTCYP3A4AHR | |
| SCHEMBL90504 | 0.83 | MEN1 (0.69) | MEN1KMT2AMAPTCYP3A4AHR | |
| Arundine SCHEMBL325162 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTCYP3A4AHR | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | MEN1KMT2AMAPTCYP3A4AHR | |
| Indole-3-Carbinol SCHEMBL29350358 | 0.80 | MEN1 (0.72) | MEN1KMT2AMAPTCYP3A4AHR | |
| Arundine SCHEMBL28335217 | 0.80 | MEN1 (0.95) | MEN1KMT2AMAPTCYP3A4AHR | |
| Indole-3-Carbinol SCHEMBL2867957 | 0.80 | MEN1 (0.72) | MEN1KMT2AMAPTCYP3A4AHR | |
| Indole-3-Carbinol SCHEMBL195520 | 0.80 | MEN1 (0.72) | MEN1KMT2AMAPTCYP3A4AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | claimed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-106928231-B | Novel EGFR wild type and mutant kinase inhibitors | 合肥中科普瑞昇生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | PRECEDO PHARMACEUTICALS CO., LTD. (CN) | 2020-09-22 | — | — | US | disclosed |
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | disclosed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | TEIJIN, LIMITED (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1477490-A1 | PYRROLOPYRIMIDINE DERIVATIVE | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | EGFR, ERBB2, ERBB3 | MEN1 4409/4885KMT2A 3292/4885MAPT 4560/4885 |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | EGFR, ERBB2, ERBB3 | MEN1 4499/4885KMT2A 3015/4885MAPT 4503/4885 |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | MEN1 3834/4885KMT2A 1064/4885MAPT 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.